BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$7.52 USD
-0.33 (-4.20%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $7.51 -0.01 (-0.13%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
BioCryst Pharmaceuticals, Inc. [BCRX]
Reports for Purchase
Showing records 61 - 80 ( 176 total )
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Notes from the AAAAI Meeting and Competitive Update
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
As Pipeline Programs Advance, We Look to OPuS-2 Results in 4Q; Affirm Buy
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
2015 to be Back Half Driven as we Await Additional HAE Data; Reit Buy and $24 PT
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Discontinuation of Coverage of the Biotech Sector
Provider: Brinson Patrick Securities Corporation
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Orphan Drug BCX4161 Granted Fast Track Designation in HAE
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Multiple Data Readouts to Drive Upside in 2015
Provider: Brinson Patrick Securities Corporation
Analyst: JAMES C
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rapivab Approval Clears the Way for a Large Stockpile Order
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
With OPuS-2 Underway, ''4161 Has Effectively Gone Pivotal
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
OPuS-2 Initiation is Imminent and Likely Pivotal; Rapivab PDUFA Next Week
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
OPuS-2 Initiation is Imminent and Likely Pivotal; Rapivab PDUFA Next Week
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Value-Driving OPuS-2 Study on Track for 4Q Start, with Two New HAE Agents to Follow in 2015; Reit Buy and $24 PT
Provider: H.C. WAINWRIGHT & CO., INC.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q Recap; OPuS-2 Trial Initiation and Likely Rapivab Approval in 4Q14
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioCryst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.